It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hepatic stellate cells (HSCs) are essential for liver fibrosis. E6 associated protein (E6AP) is one of the E3-ubiquitin-protein ligase and has been studied in proliferation and cellular stress. Currently, no information is available on the role of E6AP on transforming growth factor-β (TGF-β) signaling and hepatic fibrogenesis. This study examined whether E6AP is overexpressed in activated HSCs, and if so, its effect on hepatic fibrogenesis and the molecular mechanism. E6AP was expressed higher in HSCs than hepatocytes, and was up-regulated in activated HSCs, HSCs from the livers of carbon tetrachloride-injected mice, or TGF-β-treated LX-2 cells. The TGF-β-mediated E6AP up-regulation was not due to altered mRNA level nor protein stability. Thus, we performed microRNA (miRNA, miR) analysis and found that miR-302c was dysregulated in TGF-β-treated LX-2 cells or activated primary HSCs. We revealed that miR-302c was a modulator of E6AP. E6AP overexpression inhibited TGF-β-induced expression of plasminogen activator inhibitor-1 in LX-2 cells, albeit it was independent of Smad pathway. Additionally, E6AP inhibited TGF-β-mediated phosphorylation of mitogen-activated protein kinases. To conclude, E6AP overexpression due to decreased miR-302c in HSCs attenuated hepatic fibrogenesis through inhibition of the TGF-β-induced mitogen-activated protein kinase signaling pathway, implying that E6AP and other molecules may contribute to protection against liver fibrosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Chosun University, College of Pharmacy, Gwangju, Republic of Korea (GRID:grid.254187.d) (ISNI:0000 0000 9475 8840)
2 Chosun University, College of Pharmacy, Gwangju, Republic of Korea (GRID:grid.254187.d) (ISNI:0000 0000 9475 8840) ; Dongshin University, College of Korean Medicine, Naju, Republic of Korea (GRID:grid.412069.8) (ISNI:0000 0004 1770 4266)
3 Chosun University, Department of Pathology, College of Dentistry, Gwangju, Republic of Korea (GRID:grid.254187.d) (ISNI:0000 0000 9475 8840)
4 Woosuk University, College of Pharmacy, Wanju, Republic of Korea (GRID:grid.412965.d) (ISNI:0000 0000 9153 9511)
5 Chosun University, College of Medicine, Gwangju, Republic of Korea (GRID:grid.254187.d) (ISNI:0000 0000 9475 8840)
6 Seoul National University, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul, Republic of Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)